BRIO NEUROSTIMULATION SYSTEM
ABBOTT MEDICAL · Decision date Jun 12, 2015
What did the FDA approve?
The June 12, 2015 PMA approval for the Brio Neurostimulation System covers two indications. The first is bilateral stimulation of the subthalamic nucleus as adjunctive therapy to reduce some symptoms of advanced levodopa-responsive Parkinson's disease not adequately controlled by medications. The second is unilateral or bilateral stimulation of the ventral intermediate nucleus of the thalamus for suppression of disabling upper extremity tremor in adult essential tremor patients whose tremor is not adequately controlled by medications and constitutes a significant functional disability.
The applicant is Abbott Medical, and the device is categorized as an implanted electrical stimulator for parkinsonian tremor under product code MHY. The FDA statement reports the approved intended uses but does not itself provide clinical data or an independent effectiveness finding. No supplement type or reason is listed, so this record reflects the original PMA approval scope rather than a change to an existing approval.
FDA approval order statement
APPROVAL FOR THE BRIO NEUROSTIMULATION SYSTEM. THIS DEVICE IS INDICATED FOR THE FOLLOWING CONDITIONS:1) BILATERAL STIMULATION OF THE SUBTHALAMIC NUCLEUS (STN) AS AN ADJUNCTIVE THERAPY TO REDUCE SOME OF THE SYMPTOMS OF ADVANCED LEVODOPA-RESPONSIVE PARKINSONS DISEASE THAT ARE NOT ADEQUATELY CONTROLLED BY MEDICATIONS; AND 2) UNILATERAL OR BILATERAL STIMULATION OF THE VENTRAL INTERMEDIATE NUCLEUS (VIM) OF THE THALAMUS FOR THE SUPPRESSION OF DISABLING UPPER EXTREMITY TREMOR IN ADULT ESSENTIALTREMOR PATIENTS WHOSE TREMOR IS NOT ADEQUATELY CONTROLLED BY MEDICATIONS AND WHERE THE TREMOR CONSTITUTES A SIGNIFICANT FUNCTIONAL DISABILITY.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Neurology
- Decision date
- Jun 12, 2015
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P140009
- Regulatory pathway
- Premarket approval application
- Applicant
- ABBOTT MEDICAL
- Product code
- MHY
- Decision code
- APPR
- Decision date
- Jun 12, 2015
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, electrical, implanted, for parkinsonian tremor.
- Applicant
- Abbott Medical
- Product code
- MHY
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P140009 received
Application receipt date recorded by FDA.
P140009 · FDA decision
APPR
P140009/S140 · Related supplement
Deep Brain Stimulation (DBS) Implantable Pulse Generator (IPG) Charger
P140009/S139 · Related supplement
Infinity DBS IPG
P140009/S143 · Related supplement
Liberta RC Deep Brain Stimulation (DBS) Implantable Pulse Generator
P140009/S141 · Related supplement
Deep Brain Stimulation (DBS) EPG
P140009/S142 · Related supplement
Deep Brain Stimulation (DBS) Implantable Pulse Generator (IPG) Charger
P140009/S144 · Related supplement
Deep Brain Stimulation (DBS) Implantable Pulse Generator (IPG)
Timeline entries are records held by MedtechLedger for P140009. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P140009
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ABBOTT MEDICAL | PMA supplement | Sep 11, 2026 | FDA | |
Infinity DBS IPGP140009/S139 | ABBOTT MEDICAL | PMA supplement | Sep 23, 2026 | FDA |
| ABBOTT MEDICAL | PMA supplement | Oct 27, 2026 | FDA | |
Deep Brain Stimulation (DBS) EPGP140009/S141 | ABBOTT MEDICAL | PMA supplement | Oct 28, 2026 | FDA |
| ABBOTT MEDICAL | PMA supplement | Oct 30, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Oct 30, 2026 | FDA |
Explore the linked device profile
Other records with product code MHY
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic, Inc. | PMA supplement | Nov 8, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Oct 30, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Oct 29, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Oct 6, 2026 | FDA | |
MEDTRONIC ACTIVA TREMOR CONTROL SYSTEMP960009/S546 | Medtronic, Inc. | PMA supplement | Sep 24, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Abbott Medical
- Headquarters
- Not reported
- Brand website
- abbott.com
- FDA applicant address
- 6901 Prestion Rd., Plano, TX, 75024
Sources and methodology
- Original FDA record: P140009
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
